Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAMP: Allogeneic MSCs in Amputation
NCT02685098Phase 1Completed
- Sponsor
- Indiana University
- Start
- Jan 2017
- Primary completion
- Oct 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic bone marrow-derived mesenchymal stromal cells in critical limb ischemia (CLI) (5 arms), sponsored by Indiana University. Primary endpoint: Number of participants with treatment-related adverse events at 6 months. Started Jan 2017; status: completed.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT02685098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685098.